Women with false positive mammograms more likely to develop breast cancer, study finds

NewsGuard 100/100 Score

Women who receive a false positive mammography result are more likely to develop breast cancer over the subsequent 20 years, report researchers from Karolinska Institutet in a study published in JAMA Oncology. The risk is highest for women aged between 60 and 75 and who have low breast density.

In global terms, breast cancer is the most common form of cancer among women, and screening is an important tool for catching women with a tumor at the earliest possible stage. In Sweden, all women between 40 and 74 are invited for screening at 18 to 24-month intervals.

At each screening visit, approximately three per cent of the women who undergo screening have a false positive result, which means that they are recalled for further examination without any cancer diagnosis. False-positive mammography results can cause psychological anxiety and influence screening attendance. Previous studies indicated that false-positive mammography results were associated with a short-term increased risk of breast cancer.

The new study shows that women with false-positive results are more likely to develop breast cancer than other women over the subsequent 20 years, facing, on average, a 60 per cent increased risk, suggesting the increased risk is long-term. In this study, the researchers identified 45,213 women with an initial false positive result and 452,130 women of the same age who were not recalled, all of whom attended the mammography screening program in Stockholm. Additionally, the researchers included 12,243 women with information on mammographic density from the Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA) study.

"The elevated risk was higher in women in the 60–75 age-bracket than in the 40–49 age-bracket, and in women with low rather than high mammographic density," says Xinhe Mao, postdoctoral researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet in Sweden. "The risk was also highest in the four to six years following a false positive result."

"It's important to accentuate a long-term awareness of breast cancer in women who get false positive mammography results," says Mao. "It might be beneficial to draw up personal monitoring programs for these women with careful follow-ups over the years immediately following."

The study formed part of Xinhe Mao's doctoral thesis, and she will now continue her research with the aim to motivate more women to undergo regular mammography screening.

Radiology and breast cancer screening are currently in a phase of rapid development, partly thanks to the use of AI. Our published paper is part of the general efforts to achieve better screening results and increase the screening programme uptake."

Kamila Czene, Study's Last Author, Professor, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet

The study was financed by the Swedish Research Council, the Swedish Cancer Society, Region Stockholm, the Swedish Research Council for Health, Working Life and Welfare (FORTE) and the China Scholarship Council.

Source:
Journal reference:

Mao, X., et al. (2023). Breast Cancer Incidence After a False-Positive Mammography Result. JAMA Oncology. doi.org/10.1001/jamaoncol.2023.4519.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer